EB-DNK101 dual-targeting CAR-NK cells (MSLN + MUC1) Clinical Trials

1 actively recruiting trial

Also known as: MSLN/MUC1 Dual-CAR NK, Dual-target CAR-NK (MSLN/MUC1)

Pipeline

Phase 1/2: 1

Top Sponsors

Beijing Biotech1

Indications

Unresectable Locally Advanced or Metastatic Disease1
Pancreatic Ductal Adenocarcinoma (PDAC)1
Cancer1

Other1 trial

Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.